1. Home
  2. Clinical

Tags : Clinical

GSK Presents Results of Maternal & Older Adults RSV Vaccines at IDWeek 2020

GSK Presents Results of Maternal & Older Adults RSV Vaccines

Tuba Khan October 22, 2020

Shots: GSK reported that its RSV vaccines for maternal immunization (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in P-I/II clinical studies. Both the candidate vaccines contain a recombinant RSVPreF3, that triggers the required immune response The GSK3844766A was first tested in 48 healthy adults (18-40yrs.) & then in 1005 healthy older adults […]Read More

Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease

Roche and Prothena to Advance Prasinezumab in P-IIb Study for

Tuba Khan October 21, 2020

Shots: The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with disease modification in the PASADENA study The study is designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA study to include patients […]Read More

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to

Tuba Khan October 15, 2020

Shots:  The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the […]Read More

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Vartika Singh January 10, 2020

Shots: The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing outlined in the terms of the original collaboration agreement The companies have expanded their collaboration for bempeg + nivolumab from three ongoing registrational trials targeted […]Read More

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat

Vartika Singh January 8, 2020

Shots: • The companies enter into a collaboration to conduct a study assessing the combination of Innovent’s Tyvyt (sintilimab injection) and Sirnaomics’ RNAi drug candidate STP705 (cotsiranib) in advanced cancers including Hepatocellular Carcinomas (HCC) • The agreement will be the first example evaluating the combination of RNAi drug candidate, cotsiranib & immune checkpoint Ab, sintilimab […]Read More

InxMed Signs a Clinical Trial Collaboration with Merck & Co for Patients with Pancreatic Cancer

InxMed Signs a Clinical Trial Collaboration with Merck & Co

Vartika Singh January 7, 2020

Shots: InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial   The focus of the collaboration is to evaluate the combination of InxMed’s IN10018 plus Merck’s pembrolizumab in patients with pancreatic cancer IN10018 (formerly BI853520) is an investigational selective ATP-competitive […]Read More

Exelixis Signs a Clinical Trial Collaboration with Roche for Patients with Solid Tumors

Exelixis Signs a Clinical Trial Collaboration with Roche for Patients

Vartika Singh December 19, 2019

Shots: The companies will co-fund the clinical trial which is expected to include three P-III trials for advanced non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and renal cell carcinoma (RCC) The focus of the collaboration is to evaluate Exelixis’ Cabometyx (cabozantinib) with Roche’s Tecentriq (atezolizumab) in patients with locally advanced or metastatic solid […]Read More

SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors

SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat

Vartika Singh August 12, 2019

Shots: The companies collaborate to conduct P-I/II clinical trial assessing CyPep-1 in patients to treat advanced solid cancers. SMS-Oncology will focus on developing protocol and giving guidance on patient inclusion criteria plus investigational sites for further movement to clinic The P-I/II multicenter trial will be conducted in Europe evaluating safety, efficacy & PK or intratumoral […]Read More

Copyright ©2020 PharmaShots | Powered by Octavus Consulting